Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation-Reference-Cited by-同舟云学术

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation

Published:2015-11 Issue:11 Volume:15 Page:687-693
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Kazmi Syed M.,Nusrat Maliha,Gunaydin Hilal,Cornelison Amanda M.,Shah Nina,Kebriaei Partow,Nieto Yago,Parmar Simrit,Popat Uday R.,Oran Betul,Shah Jatin J.,Orlowski Robert Z.,Champlin Richard E.,Qazilbash Muzaffar H.,Bashir Qaiser

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference21 articles.

1. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome;Avet-Loiseau;Blood,2007

2. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation;Chang;Bone Marrow Transplant,2005

3. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation;Inamoto;Am J Hematol,2009

4. Presentation and risk stratification—improving prognosis for patients with multiple myeloma;Lonial;Cancer Treat Rev,2010

5. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2;Munshi;Blood,2011

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical utility of 7-probe FISH panel in multiple myeloma in a resource-constrained setting: A retrospective and prospective observational study;Cancer Research, Statistics, and Treatment;2024-04

2. CAR T therapies in multiple myeloma: unleashing the future;Cancer Gene Therapy;2024-03-04

3. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma;Transplantation and Cellular Therapy;2023-12

4. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma;Nature Communications;2023-11-18

5. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond;Vaccines;2023-11-16